Tokman Alexander Y 4

What Happened Alexander Y. Tokman, CEO of ENDRA Life Sciences, was granted 75,000 restricted stock units (RSUs) on January 21, 2026. The award was reported as an acquisition at a $0.00 per-share price (total immediate cash = $0). The RSUs convert to common stock on a one-for-one basis and will vest in full on January 21, 2027.

Key Details

• Transaction date: 2026-01-21; Filing date (Form 4): 2026-01-23 (timely — within the standard two business days).
• Transaction type/code: Grant / Award (A); reported acquisition price $0.00.
• Quantity: 75,000 RSUs; these convert 1:1 to common shares upon vesting (see footnote F1).
• Shares owned after transaction: Not disclosed in the provided filing details.
• No 10b5-1 plan, tax-withholding sale, or option exercise reported in this transaction.
• Filing accession: 0001193125-26-021411.

Context RSU grants are a form of compensation and do not involve an immediate cash purchase or sale of stock. The economic value of the award will depend on ENDRA’s share price at vesting (Jan 21, 2027). Such grants are common for executives and primarily reflect compensation, not a direct buying or selling signal.